Cabaletta Bio, Inc.: shareholders and insiders

CABANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.94

November 20, 2026Market cap $202M

What Ploutos Investor adds for Cabaletta Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 27% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.28 then, $0.94 on Nov 20, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Jun 10, 2026, from their own Form 4 filings.

5 Form 4s

Bought on the market

$296.2K

8 people

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

  • Jan 21, 2026Michael GerardGeneral Counsel
    Kind
  • Jan 21, 2026Mark Simon
    Kind
  • Jan 21, 2026Steven NichtbergerPresident & CEO
    Kind
  • Jan 21, 2026Catherine Bollard
    Kind
  • Jan 21, 2026Steve GavelChief Commercial Officer
    Kind
  • Jan 21, 2026Shawn Tomasello
    Kind
  • Jan 21, 2026Gwendolyn BinderPresident, Science & Tech.
    Kind
  • Jan 21, 2026David J. ChangChief Medical Officer
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 10, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by CABA's officers and directors from 2019 up to November 21, 2025, 7 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

7 Holders over 5%Nov 12, 2026 Latest filing
  • T. Rowe Price Investment Management, Inc.
    Share of class13.1%
  • Jennison Associates LLC
    Share of class11.4%
  • Prudential Financial
    Share of class11.4%
  • Bain Capital Life Sciences Opportunities III, LP
    Share of class9.99%
  • Adage Capital Management, L.P.with 2 more persons
    Share of class8.43%
  • BlackRock, Inc.
    Share of class7.70%
  • Cormorant Asset Management, LPwith 1 more person
    Share of class5.95%
Fell to 5% or less (7)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Norges Bank4.02%Nov 12, 202613G/A
  • Vanguard Capital Management3.79%Oct 30, 202613G/A
  • Millennium Management LLC1.30%Jul 23, 202613G/A
  • Alyeska Investment Group, L.P.4.67%Feb 17, 202613G/A
  • Citadel Advisors LLC3.40%Nov 14, 202513G/A
  • Nichtberger Steven3.30%Aug 11, 202513G/A
  • The Vanguard Group3.83%Jul 29, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter-23%
  • Millennium Mgmt (Englander)
    In the quarter-69%
  • D.E. Shaw
    In the quarter
  • Renaissance Technologies
    In the quarter-82%
  • AQR Capital
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 18.2% of its shares outstanding were held short, +1.7% since the report before.

Shares held short
39.29M
18.2%
Since the report before38.61M on Sep 30, 2026
+1.7%
7.2
5.44M
More days to cover thanof 4,578 US-listed companies with enough volume
79%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 6.28M
  • Nov 15, 2023: Shares held short 5.06M
  • Nov 30, 2023: Shares held short 5.67M
  • Dec 15, 2023: Shares held short 5.63M
  • Dec 29, 2023: Shares held short 6.22M
  • Jan 12, 2024: Shares held short 6.42M
  • Jan 31, 2024: Shares held short 6.39M
  • Feb 15, 2024: Shares held short 6.83M
  • Feb 29, 2024: Shares held short 7.01M
  • Mar 15, 2024: Shares held short 7.09M
  • Mar 28, 2024: Shares held short 8.50M
  • Apr 15, 2024: Shares held short 9.87M
  • Apr 30, 2024: Shares held short 10.25M
  • May 15, 2024: Shares held short 9.10M
  • May 31, 2024: Shares held short 9.47M
  • Jun 14, 2024: Shares held short 9.45M
  • Jun 28, 2024: Shares held short 7.18M
  • Jul 15, 2024: Shares held short 7.51M
  • Jul 31, 2024: Shares held short 8.77M
  • Aug 15, 2024: Shares held short 6.28M
  • Aug 30, 2024: Shares held short 6.39M
  • Sep 13, 2024: Shares held short 6.39M
  • Sep 30, 2024: Shares held short 5.32M
  • Oct 15, 2024: Shares held short 3.78M
  • Oct 31, 2024: Shares held short 3.71M
  • Nov 15, 2024: Shares held short 3.60M
  • Nov 29, 2024: Shares held short 4.50M
  • Dec 13, 2024: Shares held short 6.22M
  • Dec 31, 2024: Shares held short 6.02M
  • Jan 15, 2025: Shares held short 6.45M
  • Jan 31, 2025: Shares held short 6.25M
  • Feb 14, 2025: Shares held short 6.20M
  • Feb 28, 2025: Shares held short 6.76M
  • Mar 14, 2025: Shares held short 6.23M
  • Mar 31, 2025: Shares held short 6.13M
  • Apr 15, 2025: Shares held short 5.80M
  • Apr 30, 2025: Shares held short 6.10M
  • May 15, 2025: Shares held short 5.52M
  • May 30, 2025: Shares held short 6.20M
  • Jun 13, 2025: Shares held short 6.47M
  • Jun 30, 2025: Shares held short 5.61M
  • Jul 15, 2025: Shares held short 6.54M
  • Jul 31, 2025: Shares held short 6.03M
  • Aug 15, 2025: Shares held short 6.31M
  • Aug 29, 2025: Shares held short 5.82M
  • Sep 15, 2025: Shares held short 5.57M
  • Sep 30, 2025: Shares held short 6.04M
  • Oct 15, 2025: Shares held short 11.22M
  • Oct 31, 2025: Shares held short 12.95M
  • Nov 14, 2025: Shares held short 16.20M
  • Nov 28, 2025: Shares held short 18.11M
  • Dec 15, 2025: Shares held short 18.95M
  • Dec 31, 2025: Shares held short 18.80M
  • Jan 15, 2026: Shares held short 18.44M
  • Jan 30, 2026: Shares held short 18.68M
  • Feb 13, 2026: Shares held short 18.63M
  • Feb 27, 2026: Shares held short 18.64M
  • Mar 13, 2026: Shares held short 19.04M
  • Mar 31, 2026: Shares held short 19.97M
  • Apr 15, 2026: Shares held short 19.64M
  • Apr 30, 2026: Shares held short 20.63M
  • May 15, 2026: Shares held short 22.84M
  • May 29, 2026: Shares held short 22.94M
  • Jun 15, 2026: Shares held short 26.24M
  • Jun 30, 2026: Shares held short 34.06M
  • Jul 15, 2026: Shares held short 41.01M
  • Jul 31, 2026: Shares held short 40.78M
  • Aug 14, 2026: Shares held short 42.80M
  • Aug 31, 2026: Shares held short 41.44M
  • Sep 15, 2026: Shares held short 33.33M
  • Sep 30, 2026: Shares held short 38.61M
  • Oct 15, 2026: Shares held short 39.29M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading56.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 56.5% of the shares in the reported trades were short sales, against 44.2% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
56.5%
The 14 beforeOct 14, 2026 – Nov 2, 2026
44.2%
Change
+12.3 pts
Short sales a dayon average, of 2.28M shares
1.29M
More than atof 3,666 US-listed companies, same days
72%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 39.1%
  • Oct 15, 2026: Short sales 27.3%
  • Oct 16, 2026: Short sales 33.7%
  • Oct 19, 2026: Short sales 33.6%
  • Oct 20, 2026: Short sales 52.4%
  • Oct 21, 2026: Short sales 53%
  • Oct 22, 2026: Short sales 45.7%
  • Oct 23, 2026: Short sales 47.9%
  • Oct 26, 2026: Short sales 51.9%
  • Oct 27, 2026: Short sales 46.5%
  • Oct 28, 2026: Short sales 46.2%
  • Oct 29, 2026: Short sales 69.2%
  • Oct 30, 2026: Short sales 54.5%
  • Nov 2, 2026: Short sales 40.1%
  • Nov 3, 2026: Short sales 57.9%
  • Nov 4, 2026: Short sales 56.1%
  • Nov 5, 2026: Short sales 38.1%
  • Nov 6, 2026: Short sales 53.7%
  • Nov 9, 2026: Short sales 51%
  • Nov 10, 2026: Short sales 55.9%
  • Nov 11, 2026: Short sales 55.7%
  • Nov 12, 2026: Short sales 68.6%
  • Nov 13, 2026: Short sales 55.5%
  • Nov 16, 2026: Short sales 52.8%
  • Nov 17, 2026: Short sales 71.4%
  • Nov 18, 2026: Short sales 67.3%
  • Nov 19, 2026: Short sales 65.9%
  • Nov 20, 2026: Short sales 57.2%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

1.28M Insiders' shares1.15% Of the company
  • Steven NichtbergerPresident & CEO
    Directly1.03M
  • Mark SimonDirector
    Directly147.2K
  • Gwendolyn BinderPresident, Science & Tech.
    Directly31.3K
  • Shawn TomaselloDirector
    Directly–
  • Steve GavelChief Commercial Officer
    Directly22.2K
  • David J. ChangChief Medical Officer
    Directly8,800
  • Michael GerardGeneral Counsel
    Directly6,600
  • Catherine BollardDirector
    Directly5,405

A lower bound: it counts only the 8 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

12 ETFs holding it0.15% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.15%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.10%
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.08%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.03%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.01%
  • DFASDimensional U.S. Small Cap ETF
    Weight in the fund0.01%

12 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

140 Managers, Q2 2026$493M Value of their positions
  • Q3 2025: Managers 75
  • Q4 2025: Managers 95
  • Q1 2026: Managers 109
  • Q2 2026: Managers 140

Institutional investors by quarter

The fund managers holding CABA, quarter by quarter, from Q4 2019 to Q2 2025, 23 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 140 managers held 159M shares, worth $493M. During the quarter 54 opened a position, 24 closed one, 48 added and 20 trimmed.

The largest holders, Q2 2026

  • Jennison Associates
    In the quarter+123%
  • T. Rowe Price Investment Management
    In the quarter+70%
  • Bain Capital Life Sciences Investors
    In the quarter+78%
  • BlackRock
    In the quarter+353%
  • Adage Capital Partners Gp
    In the quarter+3.9%
  • State Street
    In the quarter×16.7
  • Vanguard Capital Management
    In the quarter+79%
  • Cormorant Asset Management
    In the quarter-9.1%
  • Price T Rowe Associates
    In the quarter+899%
  • Woodline Partners
    In the quarter+236%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Cabaletta Bio's filings show?

Who buys and sells is one part of Cabaletta Bio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CABA's shareholders

Didn't find what you were looking for?

Ask us
Have CABA's insiders bought or sold?

From Jun 10, 2026 to Jun 10, 2026 Cabaletta Bio's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold CABA?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $5.2M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.